Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Institute for Clinical Economic Review Final Report on RA Treatments

Mary Beth Nierengarten  |  Issue: June 2017  |  May 4, 2017

Specifically, she took aim at the model framework used to calculate cost, emphasizing that it is inconsistent with the recommendations of the 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis, which recommends a treat-to-target strategy.

“In the clinic, we measure disease activity, not an ACR20 response, to determine appropriate treatment,” she says, adding that she is also concerned about the limited treatment options allowed in the report and, especially, the final palliative care sequence.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“The ACR 2015 RA [guideline does] not limit treatment to three TIMs, nor are patients placed on palliative care/conventional DMARD treatment after three switches,” she wrote in a letter to ICER prior to the final publication of the report. “The ideal target should be low disease activity or remission, as determined by the clinician and the patient,” she said.

ACR President Sharad Lakhanpal, MD, MBBS, also expressed concern over the potential for limited access to appropriate care based on the report’s findings. While acknowledging the importance of comparative effectiveness research (CER), he stresses the importance of not limiting treatment options for patients. “Ideally, CER would highlight the need for multiple treatment options to address heterogeneous groups of patients with individual and unique co-morbidities,” he said in a press release.4 “The ACR is concerned that the ICER report, while based on a commonly used method to assess cost effectiveness, provides insufficient information on model structure and validation.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Tindall also expressed concerns over the calculations used to assess the cost of TIMs, highlighting the failure in the report to include rebates/vouchers, infusion facility costs, direct out-of-pocket costs, time off work for infusion, monitoring costs and office vs. hospital charges.

“If you’re talking about cost, why don’t you really talk about cost?” she asks, adding that the report fails as a true cost-effective research analysis due to its failure to include all relevant costs.

Looking at this in a different way, Louis Tharp, executive director and co-founder of CreakyJoints, emphasizes the need to look at cost in terms of the benefit of controlling disease. “We believe it is imperative that such a report incorporate the economic benefits to society derived from sustained worker productivity and quality of life that results from the use of biologics,” he says. “The report is inexcusably flawed with this value omitted. The report relies on short-term clinical trial data, ignoring the nearly two-decades-old benefits of substituting legs for wheelchairs.”

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Drug UpdatesPractice SupportProfessional TopicsRheumatoid Arthritis Tagged with:Institute for Clinical and Economic Review (ICER)targeted immune modulators (TIMs)Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value

Related Articles

    ACR Comments Help Inform ICER Assessment of Treatments for Lupus Nephritis & Other Rheumatic Conditions

    October 19, 2020

    The ACR submitted comments to the Institute for Clinical & Economic Review outlining key considerations that should inform independent assessment of the efficacy and cost-effectiveness of medical therapies for lupus nephritis.

    Opinion: Help Bring Drug Prices Down

    August 22, 2017

    I read with interest the articles in the June issue of The Rheumatologist pertaining to high drug costs. Simon Helfgott rheuminated on it, and Susan Bernstein, a medical journalist, wrote a two-page article titled “Concerns About Cost.” Both articles were thoughtful summaries of a complex issue, putting large question marks over both initial prices and…

    Humira, Rituxan Top List of U.S. Drugs with Biggest Price Increases

    October 9, 2019

    NEW YORK (Reuters)—AbbVie Inc.’s rheumatoid arthritis drug Humira (adalimumab) and Roche Holding AG’s cancer drug Rituxan (rituximab) topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.1 The price hikes were more than twice the rate of…

    Total Knee Replacement Cost-Effective, Even with Obesity & Comorbidities

    March 29, 2021

    (Reuters Health)—Total knee replacement surgery can be a cost-effective procedure for patients with severe obesity and osteoarthritis (OA), even when they also have comorbidities such as cardiovascular disease or type 2 diabetes, a new study suggests. Researchers did a cost-benefit analysis for two patient populations (over 65 years, and age 50 to 65) who had…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences